Vaxxinity, Inc. (VAXX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vaxxinity, Inc. (VAXX) trades at $0.0001. Vaxxinity, Inc. is a biotechnology company focused on developing immunotherapeutic vaccines for chronic diseases. Their pipeline targets Alzheimer's, Parkinson's, migraines, and cardiovascular disease, along with a COVID-19 vaccine. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for VAXX: VAXX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VAXX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VAXX: 3/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Vaxxinity, Inc. (VAXX) Healthcare & Pipeline Overview
Vaxxinity, Inc. is a biotechnology company developing immunotherapeutic vaccines targeting major chronic diseases such as Alzheimer's and Parkinson's, alongside cardiovascular and migraine treatments, and a COVID-19 vaccine. Their focus on innovative vaccine technology positions them within the competitive biotechnology landscape, addressing significant unmet medical needs.
What Is the Investment Thesis for VAXX?
Vaxxinity's investment thesis hinges on the successful development and commercialization of its innovative immunotherapeutic vaccines. The company's focus on chronic diseases with large patient populations presents significant market opportunities. Key value drivers include the progression of UB-311 through Phase 2 trials for Alzheimer's disease, with potential for breakthrough therapy designation and accelerated approval. Positive Phase 1 results for UB-312 in Parkinson's disease could also drive investor interest. The Phase 3 trial results for UB-612, the COVID-19 vaccine, are a near-term catalyst. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from established pharmaceutical companies. With a market cap of $0.00B and a P/E ratio of -0.22, Vaxxinity is a high-risk, high-reward investment opportunity.
Based on FMP financials and quantitative analysis
VAXX Key Highlights
UB-311 is in Phase 2 clinical trials targeting Alzheimer's disease, a market with significant unmet needs.
- UB-312 is in Phase 1 clinical trials for Parkinson's disease and other synucleinopathies.
- UB-612, a COVID-19 vaccine, is in Phase 3 clinical trials, representing a near-term potential revenue stream.
- The company's anti-PCSK9 vaccine targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events.
- Vaxxinity's innovative vaccine platform aims to stimulate the body's own immune system to fight against disease-causing proteins.
Who Are VAXX's Competitors?
VAXX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VAXX's Key Strengths?
Innovative vaccine platform technology.
- Diverse pipeline of vaccine candidates targeting major chronic diseases.
- Experienced management team with expertise in vaccine development.
- Phase 2 clinical trial underway for Alzheimer's disease vaccine.
What Are VAXX's Weaknesses?
Limited financial resources.
- High dependence on clinical trial outcomes.
- Lack of commercialized products.
- OTC market listing.
What Could Drive VAXX Stock Higher?
Phase 2 clinical trial results for UB-311 in Alzheimer's disease expected in late 2026.
- Phase 1 clinical trial results for UB-312 in Parkinson's disease expected in mid-2026.
- Phase 3 clinical trials for UB-612 COVID-19 vaccine.
- Potential partnerships with pharmaceutical companies for commercialization of vaccine candidates.
- Regulatory approvals for vaccine candidates in key markets.
What Are the Key Risks for VAXX?
Financial-distress signal — its Altman Z-Score of -15.19 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-0.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures could significantly impact the company's valuation.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from established pharmaceutical companies with greater resources.
- Limited financial resources and dependence on external funding.
- Risks associated with operating on the OTC market.
What Are the Growth Opportunities for VAXX?
- Advancement of UB-311 in Alzheimer's Disease: The Alzheimer's disease market represents a significant growth opportunity for Vaxxinity. Positive results from the Phase 2 clinical trial could lead to accelerated development and potential FDA approval. The global Alzheimer's disease market is projected to reach $12.6 billion by 2028, offering a substantial revenue opportunity for a successful therapy.
- Development of UB-312 for Parkinson's Disease: Parkinson's disease is another major area of unmet medical need. Successful development of UB-312 could provide a valuable treatment option for patients with Parkinson's and other synucleinopathies. The global Parkinson's disease market is expected to reach $5.6 billion by 2027.
- Commercialization of UB-612 COVID-19 Vaccine: The COVID-19 vaccine market remains relevant, particularly for booster shots and addressing emerging variants. Successful Phase 3 trial results and subsequent regulatory approval could generate near-term revenue for Vaxxinity. While the market is competitive, a differentiated vaccine with improved efficacy or safety could capture a significant share.
- Expansion into Migraine Treatment with UB-313: Migraines affect a large percentage of the population, and there is a growing demand for effective and well-tolerated treatments. UB-313 targets calcitonin gene-related peptide (CGRP) to fight migraines. The global migraine market is projected to reach $3.5 billion by 2027.
- Cardiovascular Disease Prevention with Anti-PCSK9 Vaccine: Cardiovascular disease remains a leading cause of death worldwide. An anti-PCSK9 vaccine could offer a novel approach to lowering LDL cholesterol and reducing the risk of cardiac events. The global cardiovascular disease market is projected to reach $27.3 billion by 2028.
What Opportunities Does VAXX Have?
- Partnerships with pharmaceutical companies.
- Expansion into new therapeutic areas.
- Accelerated regulatory pathways for breakthrough therapies.
- Growing demand for effective treatments for chronic diseases.
What Are VAXX's Competitive Advantages?
- Proprietary vaccine platform technology.
- Patent protection for its vaccine candidates.
- Clinical data demonstrating safety and efficacy.
- Expertise in immunotherapeutic vaccine development.
What Does VAXX Do?
Founded in 2014 and headquartered in Dallas, Texas, Vaxxinity, Inc. is a biotechnology company dedicated to developing novel immunotherapeutic vaccines aimed at combating chronic diseases. The company's core strategy revolves around its innovative vaccine platform designed to stimulate the body's own immune system to fight against disease-causing proteins. Vaxxinity's pipeline includes product candidates targeting some of the most prevalent and debilitating conditions, including Alzheimer's disease (AD), Parkinson's disease, migraines, and cardiovascular disease. Their lead product candidate, UB-311, is currently in Phase 2 clinical trials for Alzheimer's disease, targeting toxic forms of aggregated amyloid-beta in the brain. UB-312, in Phase 1, aims to address Parkinson's disease and other synucleinopathies by targeting aggregated alpha-synuclein. Additional programs include UB-313 for migraines, an anti-PCSK9 vaccine for cardiovascular disease, and UB-612, a COVID-19 vaccine in Phase 3 trials. Vaxxinity is working to establish itself as a leader in the field of immunotherapeutic vaccines, addressing significant unmet needs in neurology and other chronic diseases.
What Products and Services Does VAXX Offer?
- Develop immunotherapeutic vaccines for chronic diseases.
- Target Alzheimer's disease with UB-311, currently in Phase 2 clinical trials.
- Target Parkinson's disease and other synucleinopathies with UB-312, currently in Phase 1 clinical trials.
- Develop UB-313 for the treatment of migraines.
- Develop an anti-PCSK9 vaccine to lower LDL cholesterol and reduce the risk of cardiac events.
- Develop UB-612 for neutralizing the SARS-CoV-2 virus, currently in Phase 3 clinical trials.
How Does VAXX Make Money?
- Develop and patent novel immunotherapeutic vaccines.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA.
- Partner with pharmaceutical companies for commercialization or commercialize products independently.
What Industry Does VAXX Operate In?
Vaxxinity operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The COVID-19 vaccine market remains substantial, although increasingly competitive. Vaxxinity's success depends on its ability to differentiate its vaccine platform and navigate the complex regulatory landscape. Competitors include both large pharmaceutical companies and smaller biotech firms focused on similar therapeutic areas.
Who Are VAXX's Key Customers?
- Patients suffering from Alzheimer's disease, Parkinson's disease, migraines, and cardiovascular disease.
- Healthcare providers who prescribe and administer vaccines.
- Pharmaceutical companies that may license or acquire Vaxxinity's products.
- Government agencies and public health organizations.
Key Financial Metrics
Return on equity for Vaxxinity, Inc. stands at -0.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.1%, showing how much profit it generates from its asset base. A current ratio of 1.89 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Vaxxinity, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dallas, US. The company is led by CEO Mei Mei Hu. VAXX has traded publicly since 2021.
Financial Health
Vaxxinity, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.19 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Vaxxinity, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.41.
Insider Activity
The most recent 10 insider filings for Vaxxinity, Inc. break down as 8 sales and 2 purchases. On net that is roughly 501K shares acquired (about $555K) — insiders putting money in tends to read as conviction.
VAXX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Vaxxinity has recently seen a surge in insider buying, suggesting confidence from leadership in the company's future prospects.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach to vaccine development.
- Recent partnerships and collaborations have sparked optimism, indicating potential for expanded market reach and product offerings.
- The overall healthcare sector's focus on vaccine technology is creating a favorable environment for companies like Vaxxinity.
Bear Case
- Despite recent positive sentiment, some analysts remain cautious due to competitive pressures in the biotech space.
- There are concerns regarding the timeline for product approvals, which could delay revenue generation and impact investor confidence.
- Recent social media discussions reveal skepticism about the scalability of Vaxxinity's technology compared to larger competitors.
- Market perception is still wary, as investors recall the volatility seen in biotech stocks during uncertain regulatory environments.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VAXX Latest News
No recent news available for VAXX.
VAXX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VAXX.
Price Targets
Wall Street price target analysis for VAXX.
VAXX MoonshotScore
What does this score mean?
The MoonshotScore rates VAXX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Mei Mei Hu
CEO
Mei Mei Hu serves as the CEO of Vaxxinity, bringing extensive experience in the pharmaceutical and biotechnology industries. Prior to Vaxxinity, she held leadership positions at COVAXX and United Biomedical, Inc. Ms. Hu has a strong background in strategic planning, business development, and commercialization. She has a track record of driving growth and innovation in the healthcare sector. Her experience includes overseeing clinical trials, securing regulatory approvals, and building strategic partnerships.
Track Record: Under Mei Mei Hu's leadership, Vaxxinity has advanced its pipeline of vaccine candidates, including UB-311 into Phase 2 clinical trials for Alzheimer's disease. She has also overseen the development of UB-312 for Parkinson's disease and UB-612 for COVID-19. Her strategic focus has been on leveraging Vaxxinity's innovative vaccine platform to address unmet medical needs in chronic diseases.
VAXX OTC Market Information
The OTC Other tier, also known as the Pink Market, represents the lowest tier of the OTC market. Companies on this tier often have limited financial disclosure, may be distressed, or may not meet the minimum requirements for higher tiers like OTCQB or OTCQX. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ. Companies in this tier are not required to meet minimum financial standards and may not be current in their reporting.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of fraud and misrepresentation.
- Low liquidity makes it difficult to buy or sell shares.
- Lack of regulatory oversight increases the risk of price manipulation.
- Companies on the OTC Other tier may be financially distressed or have a history of regulatory violations.
- Higher volatility compared to stocks listed on major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Review the company's legal and regulatory history.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Experienced management team with a track record in the biotechnology industry.
- Pipeline of vaccine candidates targeting major chronic diseases.
- Ongoing clinical trials for key vaccine candidates.
- Focus on addressing unmet medical needs.
- Scientific publications or presentations supporting the company's technology.
What Investors Ask About Vaxxinity, Inc. (VAXX) — Healthcare
What does Vaxxinity, Inc. do?
Vaxxinity, Inc. is a biotechnology company focused on developing immunotherapeutic vaccines for chronic diseases. Their innovative vaccine platform aims to stimulate the body's own immune system to fight against disease-causing proteins. The company's pipeline includes vaccine candidates targeting Alzheimer's disease (UB-311), Parkinson's disease (UB-312), migraines (UB-313), cardiovascular disease (anti-PCSK9), and COVID-19 (UB-612). Vaxxinity seeks to address unmet medical needs in neurology and other chronic diseases through its novel vaccine technology.
What do analysts say about VAXX stock?
As of March 16, 2026, there is no readily available analyst consensus on VAXX stock due to its OTC listing and limited coverage. Key valuation metrics such as price-to-earnings (P/E) ratio are not meaningful due to negative earnings. Growth considerations revolve around the successful advancement of its vaccine candidates through clinical trials and potential partnerships.
What are the main risks for VAXX?
The main risks for Vaxxinity include clinical trial failures, regulatory hurdles, competition from established pharmaceutical companies, limited financial resources, and risks associated with operating on the OTC market. Clinical trial failures could significantly impact the company's valuation and future prospects. Regulatory delays or denials could also impede the commercialization of its vaccine candidates.
What are the key factors to evaluate for VAXX?
Evaluate VAXX on fundamentals, analyst consensus, and risk factors. Vaxxinity's investment thesis hinges on the successful development and commercialization of its innovative immunotherapeutic vaccines. Not financial advice.
How frequently does VAXX data refresh on this page?
VAXX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VAXX's recent stock price performance?
Vaxxinity, Inc. (VAXX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative vaccine platform technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VAXX overvalued or undervalued right now?
Vaxxinity, Inc. (VAXX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VAXX before investing?
Before investing in Vaxxinity, Inc. (VAXX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.